A multicenter, phase II, randomized, blinded, placebo-controlled trial evaluating the efficacy and safety of Sutent [sunitinib] with or without bevacizumab in first-line patients with metastatic renal cell cancer

Trial Profile

A multicenter, phase II, randomized, blinded, placebo-controlled trial evaluating the efficacy and safety of Sutent [sunitinib] with or without bevacizumab in first-line patients with metastatic renal cell cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib
  • Indications Renal cancer
  • Focus Adverse reactions
  • Acronyms SABRE-R
  • Sponsors Genentech
  • Most Recent Events

    • 14 Apr 2009 Primary endpoint changed from progression-free survival to adverse events, patient numbers amended from 100 to 16 as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Aug 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top